US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

FibroBiologics

0.3351

-0.0328-8.92%

Volume:845.43K

Turnover:294.57K

Market Cap:17.24M

PE:-0.69

High:0.3697

Open:0.3492

Low:0.3330

Close:0.3679

52wk High:2.98

52wk Low:0.3181

Shares:51.46M

Float Shares:32.07M

Volume Ratio:1.00

T/O Rate:2.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4850

EPS(LYR):-0.3395

ROE:-1292.87%

ROA:-115.62%

PB:137.94

PE(LYR):-0.99

Loading ...

Overview Company News Filings

FibroBiologics Reports Increased Losses Amidst Strategic Expansion

FibroBiologics Is Maintained at Buy by HC Wainwright & Co.

FibroBiologics price target lowered to $5 from $10 at H.C. Wainwright

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics reports Q3 EPS (13c), two estimates (12c)

FibroBiologics, Inc. - Common Stock Q3 EPS $(0.13) Misses $(0.11) Estimate

FibroBiologics posts $15.4 million net loss for nine months ended September 2025

Fibrobiologics Inc: Preparing to Submit Investigational New Drug Applications for Treatment of Psoriasis With Cyps317

THOMSON REUTERS

Press Release: FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics to Present at Bio-Europe 2025

FibroBiologics Inc. to Present at the 2025 ThinkEquity Conference

Buy Rating for FibroBiologics, Inc. Driven by Innovative Pipeline and Promising Preclinical Results

FibroBiologics Inc. to Present at Cell & Gene Meeting on the Mesa Conference

FibroBiologics publishes opinion editorial on stem cell therapies

FibroBiologics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

FibroBiologics Announces Promising IND-Enabling Updates for Fibroblast Spheroids in Psoriasis Treatment

Fibrobiologics Announces Positive Ind-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

THOMSON REUTERS

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics Inc. Announces Breakthrough Clinical Advancements in Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies

Fibrobiologics: Bone Marrow Organoids Transplantation Into Melanoma Mouse Model Reduces Tumor Size

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/FBLG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":0.3351,"timestamp":1763412516019,"preClose":0.3679,"halted":0,"volume":845434,"delay":0,"floatShares":32065900,"shares":51456077,"eps":-0.484982,"marketStatus":"Trading","change":-0.0328,"latestTime":"11-17 15:49:17 EST","open":0.3492,"high":0.3697,"low":0.333,"amount":294571.11924928,"amplitude":0.099755,"askPrice":0.3393,"askSize":100,"bidPrice":0.3361,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.484982,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1763413200000},"marketStatusCode":2,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":0.3679,"preHourTrading":{"tag":"盘前","latestPrice":0.3426,"preClose":0.3679,"latestTime":"08:47 EST","volume":24816,"amount":8724.51471408,"timestamp":1763387259749},"postHourTrading":{"tag":"盘后","latestPrice":0.3531,"preClose":0.3679,"latestTime":"19:59 EST","volume":86620,"amount":31144.55895,"timestamp":1763168368594},"volumeRatio":1.00344},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":32065900,"roa":"-115.62%","roe":"-1292.87%","lyrEps":-0.339497,"volumeRatio":1.00344,"shares":51456077,"dividePrice":0,"high":0.3697,"amplitude":0.099755,"preClose":0.3679,"low":0.333,"week52Low":0.3181,"pbRate":"137.94","week52High":2.98,"institutionHeld":0,"latestPrice":0.3351,"committee":-0.980198,"eps":-0.484982,"divideRate":0,"volume":845434,"delay":0,"ttmEps":-0.484982,"open":0.3492,"prevYearClose":2,"prevWeekClose":0.3679,"prevMonthClose":0.3933,"prevQuarterClose":0.5462,"fiveDayClose":0.3569,"twentyDayClose":0.4103,"sixtyDayClose":0.5886},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"FBLG","fiscalQuarterEnding":"2025/09","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761883200000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-07-31","symbol":"FBLG","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753934400000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1730437200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2025-11-14","current":-0.701057,"percent":0.988372,"low":-68.573467,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"high":-0.740379,"avg":-8.197896,"sd":10.726621,"marketCap":17273805},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477},{"date":"2025-04-25","current":-4.361485,"twenty":-19.501154,"median":-5.215258,"eighty":-3.131377,"marketCap":48678537},{"date":"2025-05-02","current":-3.496805,"twenty":-18.968982,"median":-5.142823,"eighty":-3.15355,"marketCap":39027837},{"date":"2025-05-09","current":-2.900977,"twenty":-18.732461,"median":-5.107537,"eighty":-3.105179,"marketCap":32377800},{"date":"2025-05-16","current":-5.090366,"twenty":-18.693381,"median":-5.090366,"eighty":-3.095239,"marketCap":39027837},{"date":"2025-05-23","current":-4.291877,"twenty":-18.607387,"median":-5.049055,"eighty":-3.101704,"marketCap":32905823},{"date":"2025-05-30","current":-3.742916,"twenty":-18.421041,"median":-5.00701,"eighty":-3.104523,"marketCap":28696939},{"date":"2025-06-06","current":-4.262932,"twenty":-18.227882,"median":-4.979847,"eighty":-3.124991,"marketCap":32683900},{"date":"2025-06-13","current":-4.354259,"twenty":-18.018955,"median":-4.934576,"eighty":-3.149603,"marketCap":33384106},{"date":"2025-06-20","current":-3.674878,"twenty":-17.856887,"median":-4.868731,"eighty":-3.157497,"marketCap":28175292},{"date":"2025-06-27","current":-3.644169,"twenty":-17.748258,"median":-4.815121,"eighty":-3.160884,"marketCap":27939844},{"date":"2025-07-03","current":-3.132347,"twenty":-17.688614,"median":-4.795627,"eighty":-3.157497,"marketCap":24015708},{"date":"2025-07-11","current":-3.321721,"twenty":-17.510817,"median":-4.711647,"eighty":-3.13343,"marketCap":25467638},{"date":"2025-07-18","current":-3.531568,"twenty":-17.278608,"median":-4.698155,"eighty":-3.14171,"marketCap":27076534},{"date":"2025-07-25","current":-3.36062,"twenty":-17.22661,"median":-4.675331,"eighty":-3.157497,"marketCap":25765873},{"date":"2025-08-01","current":-3.260303,"twenty":-17.184807,"median":-4.665775,"eighty":-3.157497,"marketCap":24996742},{"date":"2025-08-08","current":-1.692292,"twenty":-16.92818,"median":-4.639671,"eighty":-3.111465,"marketCap":22377179},{"date":"2025-08-15","current":-1.862725,"twenty":-16.567638,"median":-4.558872,"eighty":-3.098103,"marketCap":24630815},{"date":"2025-08-22","current":-1.865576,"twenty":-16.533025,"median":-4.524553,"eighty":-3.074912,"marketCap":24668515},{"date":"2025-08-29","current":-1.964732,"twenty":-16.426305,"median":-4.50321,"eighty":-3.015849,"marketCap":25979645},{"date":"2025-09-05","current":-1.881416,"twenty":-16.368618,"median":-4.425233,"eighty":-2.962429,"marketCap":24877961},{"date":"2025-09-12","current":-1.789547,"twenty":-16.310932,"median":-4.376497,"eighty":-2.933582,"marketCap":23663176},{"date":"2025-09-19","current":-1.694826,"twenty":-16.29651,"median":-4.361485,"eighty":-2.897365,"marketCap":22410690},{"date":"2025-09-26","current":-1.709716,"twenty":-15.863859,"median":-4.348021,"eighty":-2.853034,"marketCap":22607569},{"date":"2025-10-03","current":-1.710666,"twenty":-15.863859,"median":-4.327761,"eighty":-2.748074,"marketCap":22620136},{"date":"2025-10-10","current":-1.544034,"twenty":-15.807485,"median":-4.261494,"eighty":-2.486529,"marketCap":20416767},{"date":"2025-10-17","current":-1.298839,"twenty":-15.630094,"median":-4.210794,"eighty":-2.348389,"marketCap":17174548},{"date":"2025-10-24","current":-1.301056,"twenty":-15.503317,"median":-4.186877,"eighty":-2.318853,"marketCap":17203870},{"date":"2025-10-31","current":-1.257339,"twenty":-14.972667,"median":-4.132817,"eighty":-2.297962,"marketCap":16625800},{"date":"2025-11-07","current":-0.932278,"twenty":-13.927049,"median":-4.072247,"eighty":-2.249717,"marketCap":17248077},{"date":"2025-11-14","current":-0.933669,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"marketCap":17273805}],"updateTime":1763404470268},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584151336","title":"FibroBiologics Reports Increased Losses Amidst Strategic Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2584151336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584151336?lang=en_us&edition=fundamental","pubTime":"2025-11-17 11:50","pubTimestamp":1763351441,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. ( ($FBLG) ) has released its Q3 earnings. Here is a breakdown of the information FibroBiologics, Inc. presented to its investo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-reports-increased-losses-amidst-strategic-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-reports-increased-losses-amidst-strategic-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2581264417","title":"FibroBiologics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2581264417","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581264417?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:39","pubTimestamp":1762342740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 06:39 ET (11:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2581672566","title":"FibroBiologics price target lowered to $5 from $10 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2581672566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581672566?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:10","pubTimestamp":1762341032,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on FibroBiologics (FBLG) to $5 from $10 and keeps a Buy rating on the shares. The firm adjusted the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-price-target-lowered-to-5-from-10-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-price-target-lowered-to-5-from-10-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG"],"gpt_icon":0},{"id":"2580901772","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580901772","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580901772?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:18","pubTimestamp":1762172280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 07:18 ET (12:18 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2580162544","title":"FibroBiologics reports Q3 EPS (13c), two estimates (12c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580162544","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580162544?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:35","pubTimestamp":1761942917,"startTime":"0","endTime":"0","summary":"“This quarter brought our strategy into greater focus,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics (FBLG). “We are e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-reports-q3-eps-13c-two-estimates-12c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-reports-q3-eps-13c-two-estimates-12c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG"],"gpt_icon":0},{"id":"2580169564","title":"FibroBiologics, Inc. - Common Stock Q3 EPS $(0.13) Misses $(0.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2580169564","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580169564?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:31","pubTimestamp":1761942700,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 21.5 percent. This is a 1200 percent decrease over losses of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/10/48574557/fibrobiologics-inc-common-stock-q3-eps-0-13-misses-0-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"FibroBiologics, Inc. - Common Stock Q3 EPS $(0.13) Misses $(0.11) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2580928416","title":"FibroBiologics posts $15.4 million net loss for nine months ended September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580928416","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580928416?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:30","pubTimestamp":1761942617,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. reported a net loss of approximately $15.4 million for the nine months ended September 30, 2025, compared to a net loss of $8.1 million for the same period in 2024. General and administrative expenses were about $7.4 million for the first nine months of 2025, up from $6.9 million in 2024. The increase was mainly due to higher personnel costs, including stock-based compensation, increased professional fees, and travel expenses, partially offset by decreased expenses related to a Direct Listing. Cash and cash equivalents totaled approximately $4.9 million as of September 30, 2025. During the period, FibroBiologics advanced preparations to begin manufacturing its fibroblast-based spheroid product candidate, CYWC628, for a Phase 1/2 clinical trial in diabetic foot ulcer patients, scheduled for the first quarter of the following year. The company is also preparing to submit Investigational New Drug applications for CYPS317 for psoriasis and CYMS101 for multiple sclerosis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDLbCZvGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","FBLG","IE00BKPKM429.USD","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4585","LU2095319765.USD","BK4139","BK4588","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2580184416","title":"Fibrobiologics Inc: Preparing to Submit Investigational New Drug Applications for Treatment of Psoriasis With Cyps317","url":"https://stock-news.laohu8.com/highlight/detail?id=2580184416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580184416?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:30","pubTimestamp":1761942601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUACGQHT9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2580141690","title":"Press Release: FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2580141690","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580141690?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:30","pubTimestamp":1761942600,"startTime":"0","endTime":"0","summary":"Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers  patients. Preparing to submit Investigational New Drug applications for the treatment of psoriasis with CYPS317 and the treatment of multiple sclerosis with CYMS101. HOUSTON, Oct. 31, 2025  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced third quarter 2025 financial results and provided a corporate update.-- Announced positive IND-enabling updates from the psoriasis research. program demonstrating the potential of human dermal fibroblast spheroids. as a novel therapeutic approach for chronic-relapse psoriasis.-- Advanced the Bone Marrow Organoid platform, offering promising new. treatment options for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2577451147","title":"FibroBiologics to Present at Bio-Europe 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577451147","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577451147?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:30","pubTimestamp":1761309000,"startTime":"0","endTime":"0","summary":"HOUSTON, Oct.  24, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the dev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3172796/0/en/FibroBiologics-to-Present-at-Bio-Europe-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2575218392","title":"FibroBiologics Inc. to Present at the 2025 ThinkEquity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575218392","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575218392?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:30","pubTimestamp":1760445026,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts, will present at the 2025 ThinkEquity Conference on October 30 at the Mandarin Oriental in New York City. Founder and CEO Pete O'Heeron will deliver a company presentation at 4:30 p.m. ET and be available for one-on-one investor meetings throughout the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL6FvjjG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","FBLG","IE00B64PRP62.GBP","NDAQ","BK4585","LU2210150020.SGD","BK4588","BK4112","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2569100627","title":"Buy Rating for FibroBiologics, Inc. Driven by Innovative Pipeline and Promising Preclinical Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2569100627","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569100627?lang=en_us&edition=fundamental","pubTime":"2025-09-24 02:15","pubTimestamp":1758651318,"startTime":"0","endTime":"0","summary":"Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on FibroBiologics, Inc.. The associated price target is $4.00. Michael O...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-fibrobiologics-inc-driven-by-innovative-pipeline-and-promising-preclinical-results-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-fibrobiologics-inc-driven-by-innovative-pipeline-and-promising-preclinical-results-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG"],"gpt_icon":0},{"id":"2569902247","title":"FibroBiologics Inc. to Present at Cell & Gene Meeting on the Mesa Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2569902247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569902247?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:30","pubTimestamp":1758630650,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc., a clinical-stage biotechnology company, will be presenting at the 2025 Cell & Gene Meeting on the Mesa in Phoenix, Arizona. The presentation, led by Chief Scientific Officer Hamid Khoja, Ph.D., is scheduled for October 7, 2025, at 2:15 p.m. MST. The company will share updates on their fibroblast-based technologies and their potential to address unmet needs in various indications, including the initiation of a clinical trial for diabetic foot ulcers planned for early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL7j1nDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG","BK4112","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","BK4585","BK4588","LU0314104364.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2566719859","title":"FibroBiologics publishes opinion editorial on stem cell therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2566719859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566719859?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:35","pubTimestamp":1757680549,"startTime":"0","endTime":"0","summary":"FibroBiologics (FBLG) announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibrob...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrobiologics-publishes-opinion-editorial-on-stem-cell-therapies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrobiologics-publishes-opinion-editorial-on-stem-cell-therapies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2566697311","title":"FibroBiologics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2566697311","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566697311?lang=en_us&edition=fundamental","pubTime":"2025-09-12 18:38","pubTimestamp":1757673480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2025 06:38 ET (10:38 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2566995848","title":"FibroBiologics Announces Promising IND-Enabling Updates for Fibroblast Spheroids in Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2566995848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566995848?lang=en_us&edition=fundamental","pubTime":"2025-09-11 20:30","pubTimestamp":1757593853,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc., a clinical-stage biotechnology company, has announced positive updates from its psoriasis research program. The company reported favorable IND-enabling results demonstrating the potential of human dermal fibroblast  spheroids as a therapeutic approach for chronic-relapse psoriasis. Currently, FibroBiologics is expanding its research efforts by exploring repeated dosing regimens and conducting systemic and local cytokine profiling, along with histopathological assessments of skin lesions. These studies aim to deepen the understanding of the underlying mechanisms and strengthen the clinical foundation for further advancement. The results from these studies have been presented and mark a pivotal milestone in the company's path toward developing treatments for chronic inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL8ljkXM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","FBLG","BK4112"],"gpt_icon":0},{"id":"2566699301","title":"Fibrobiologics Announces Positive Ind-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2566699301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566699301?lang=en_us&edition=fundamental","pubTime":"2025-09-11 20:30","pubTimestamp":1757593801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nTUA2XHF3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2566988144","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2566988144","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566988144?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:28","pubTimestamp":1757518080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2025 11:28 ET (15:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2566067486","title":"FibroBiologics Inc. Announces Breakthrough Clinical Advancements in Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2566067486","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566067486?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:30","pubTimestamp":1757507433,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. Announces Breakthrough Clinical Advancements in Bone Marrow Organoid Platform for Cancer and Immune-Related Therapies. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL40W9bw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","FBLG","BK4588","BK4139","LU2095319765.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2566808609","title":"Fibrobiologics: Bone Marrow Organoids Transplantation Into Melanoma Mouse Model Reduces Tumor Size","url":"https://stock-news.laohu8.com/highlight/detail?id=2566808609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566808609?lang=en_us&edition=fundamental","pubTime":"2025-09-10 20:30","pubTimestamp":1757507401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA1DBZTT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}